Overview

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m^2 or Taxol 175 mg/m^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Paclitaxel